Ironwood Pharmaceuticals (IRWD) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Ironwood Pharmaceuticals (NASDAQ:IRWD) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.04, Bloomberg Earnings reports. Ironwood Pharmaceuticals had a negative return on equity of 2,458.64% and a negative net margin of 39.20%. The business had revenue of $94.20 million during the quarter, compared to analyst estimates of $88.86 million. During the same period last year, the business posted ($0.12) earnings per share. The company’s quarterly revenue was up 7.7% on a year-over-year basis.

Ironwood Pharmaceuticals (NASDAQ:IRWD) opened at $15.36 on Friday. The stock has a market capitalization of $2,321.20, a price-to-earnings ratio of -19.20 and a beta of 1.29. Ironwood Pharmaceuticals has a fifty-two week low of $12.89 and a fifty-two week high of $19.94. The company has a quick ratio of 4.86, a current ratio of 4.87 and a debt-to-equity ratio of -22.31.

Several research firms have recently commented on IRWD. BidaskClub upgraded Ironwood Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Sunday, February 11th. Zacks Investment Research upgraded Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, January 18th. Bank of America lowered Ironwood Pharmaceuticals from a “buy” rating to an “underperform” rating and lowered their price target for the stock from $20.00 to $15.00 in a research report on Friday, January 5th. ValuEngine lowered Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, December 29th. Finally, Mizuho lowered Ironwood Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $20.00 to $16.00 in a research report on Wednesday, December 6th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the stock. Ironwood Pharmaceuticals has a consensus rating of “Hold” and an average price target of $17.56.

In other Ironwood Pharmaceuticals news, insider Mark G. Currie sold 60,000 shares of the firm’s stock in a transaction on Wednesday, January 24th. The stock was sold at an average price of $15.45, for a total value of $927,000.00. Following the sale, the insider now directly owns 835,000 shares in the company, valued at $12,900,750. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Peter M. Hecht sold 113,405 shares of the firm’s stock in a transaction on Thursday, December 7th. The shares were sold at an average price of $15.12, for a total value of $1,714,683.60. Following the completion of the sale, the chief executive officer now owns 4,696,917 shares in the company, valued at $71,017,385.04. The disclosure for this sale can be found here. Over the last quarter, insiders sold 174,905 shares of company stock valued at $2,666,359. 7.63% of the stock is currently owned by company insiders.

Institutional investors have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Ironwood Pharmaceuticals by 128.6% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,010 shares of the biotechnology company’s stock valued at $135,000 after buying an additional 5,069 shares in the last quarter. Gerber Kawasaki Wealth & Investment Management acquired a new stake in Ironwood Pharmaceuticals in the third quarter valued at $170,000. Hemenway Trust Co LLC acquired a new stake in Ironwood Pharmaceuticals in the fourth quarter valued at $204,000. Ameritas Investment Partners Inc. raised its stake in Ironwood Pharmaceuticals by 5.8% in the second quarter. Ameritas Investment Partners Inc. now owns 11,821 shares of the biotechnology company’s stock valued at $223,000 after buying an additional 648 shares in the last quarter. Finally, Virtu KCG Holdings LLC raised its stake in Ironwood Pharmaceuticals by 10.3% in the second quarter. Virtu KCG Holdings LLC now owns 15,740 shares of the biotechnology company’s stock valued at $297,000 after buying an additional 1,470 shares in the last quarter.

ILLEGAL ACTIVITY NOTICE: “Ironwood Pharmaceuticals (IRWD) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/17/ironwood-pharmaceuticals-irwd-releases-quarterly-earnings-results-beats-estimates-by-0-04-eps.html.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Earnings History for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply